HOME > SEARCH > SEARCH RESULTS
Your search for pilot research returned 184 results.
Selected filters: Patients
Displaying 111 to 120 of 184 records
Sort by: Page:  << Prev 9… 10… 11… 12… 13… 14… 15… Next >>
  • FDA Task Force – Feb 11, 2020
    Charge is to create a more efficient and timely approval process for new and non-proprietary radiotracers and radiotherapeutics by the U.S. Food and Drug Administration.
  • Dose Optimization – Oct 31, 2019
    The right test with the right dose should be given to the right patient at the right time. SNMMI continually strives to ensure patients receive the best, safest and most appropriate care.
  • Phantom Analysis Toolkit (PAT) – Oct 21, 2019
    Accreditation programs are increasingly requiring phantom-based PET/CT scanner measurements to provide evidence of quantitative accuracy and qualitative clinical image quality. To help SNMMI membership meet these requirements, SNMMI is providing a cloud-based automated Phantom Analysis Toolkit (PAT).
  • New Radiotracer Can Identify Nearly 30 Types of Cancer: Future potential for therapeutic application – Jun 7, 2019
    A novel class of radiopharmaceuticals has proven effective in non-invasively identifying nearly 30 types of malignant tumors, according to research published in the June issue of The Journal of Nuclear Medicine.
  • Courtney Lawhn-Heath Awarded 2019 Henkin Fellowship – Apr 23, 2019
    SNMMI is pleased to announce that Courtney Lawhn-Heath, MD, has been selected as the recipient of the 2019 Robert E. Henkin Government Relations Fellowship.
  • HomePageContent – Aug 30, 2018
  • Fact Sheet: What is Radioimmunotherapy? – Aug 13, 2018
    Fact Sheet: What is Radioimmunotherapy?
  • Fact Sheet: What is Peptide Receptor Radionuclide Therapy (PRRT)? – Aug 13, 2018
    Fact Sheet: What is PRRT?
  • HomePageContent – Jun 24, 2018
  • About Us – Jun 11, 2018
    In October of 2008, SNMMI leadership announced the creation of the SNMMI Clinical Trials Network (CTN). The CTN is a collaborative effort assigned to address the widely recognized need for validated imaging biomarkers that can be used in streamlining the development and registration of investigational therapeutics. Standardization in molecular imaging is critical for a trial to be successful, and the elements of the CTN have been carefully developed to make it possible. CTN also works collaboratively with other imaging associations such as RSNA, government agencies such as the FDA and industry leaders to move the entire field forward.
Displaying 111 to 120 of 184 records
Page:  << Prev 9… 10… 11… 12… 13… 14… 15… Next >>